Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Holdom

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 27, 2021
Low plasma hyaluronan is associated with faster functional decline in patients with amyotrophic lateral sclerosisCory J Holdom, Shyuan T Ngo, Pamela A McCombe, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 14, 2026
Systemic immune-metabolic interactions in patients with amyotrophic lateral sclerosis: correlations of plasma cytokines with metabolic statusStephanie L Howe, Cory J Holdom, Pamela A McCombe, et al.
European Journal of Neurology|September 2, 2023
Associations of postprandial ghrelin, liver-expressed antimicrobial peptide 2 and leptin levels with body composition, disease progression and survival in patients with amyotrophic lateral sclerosisStephanie L Howe, Cory J Holdom, Pamela A McCombe, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 1, 2025
Examining the impact and role of lipid classes on the risk of amyotrophic lateral sclerosis (ALS) onset: a systematic review and GRADE analysis of the evidenceAmber R Sewell-Green, Merle Kuiper, Cory J Holdom, et al.
Ebiomedicine|May 30, 2025
Identification of passive wrist-worn accelerometry outcomes for improved disease monitoring and trial design in motor neuron diseaseCory J Holdom, Rakesh Pilkar, Christine C Guo, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 3, 2025
Lower-limb biomechanics in motor neuron disease: a joint-level perspective of gait disruptionCory J Holdom, James L Williamson, Georgia O'Reilly, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 1, 2025
Persistent high levels of perceived fatigue are not associated with hypermetabolism in patients with amyotrophic lateral sclerosisLauren E Buckett, Cory J Holdom, Stephanie L Howe, et al.
European Journal of Neurology|October 10, 2022
Lower hypothalamic volume with lower body mass index is associated with shorter survival in patients with amyotrophic lateral sclerosisJeryn Chang, Thomas B Shaw, Cory J Holdom, et al.
Journal of Neurology|February 5, 2023
Use of hip- versus wrist-based actigraphy for assessing functional decline and disease progression in patients with motor neuron diseaseCory J Holdom, Jordi W J van Unnik, Ruben P A van Eijk, et al.
European Journal of Neurology|July 3, 2021
Venous creatinine as a biomarker for loss of fat-free mass and disease progression in patients with amyotrophic lateral sclerosisCory J Holdom, Mark R Janse van Mantgem, Ruben P A van Eijk, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 27, 2021
Low plasma hyaluronan is associated with faster functional decline in patients with amyotrophic lateral sclerosisCory J Holdom, Shyuan T Ngo, Pamela A McCombe, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 14, 2026
Systemic immune-metabolic interactions in patients with amyotrophic lateral sclerosis: correlations of plasma cytokines with metabolic statusStephanie L Howe, Cory J Holdom, Pamela A McCombe, et al.
European Journal of Neurology|September 2, 2023
Associations of postprandial ghrelin, liver-expressed antimicrobial peptide 2 and leptin levels with body composition, disease progression and survival in patients with amyotrophic lateral sclerosisStephanie L Howe, Cory J Holdom, Pamela A McCombe, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 1, 2025
Examining the impact and role of lipid classes on the risk of amyotrophic lateral sclerosis (ALS) onset: a systematic review and GRADE analysis of the evidenceAmber R Sewell-Green, Merle Kuiper, Cory J Holdom, et al.
Ebiomedicine|May 30, 2025
Identification of passive wrist-worn accelerometry outcomes for improved disease monitoring and trial design in motor neuron diseaseCory J Holdom, Rakesh Pilkar, Christine C Guo, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 3, 2025
Lower-limb biomechanics in motor neuron disease: a joint-level perspective of gait disruptionCory J Holdom, James L Williamson, Georgia O'Reilly, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 1, 2025
Persistent high levels of perceived fatigue are not associated with hypermetabolism in patients with amyotrophic lateral sclerosisLauren E Buckett, Cory J Holdom, Stephanie L Howe, et al.
European Journal of Neurology|October 10, 2022
Lower hypothalamic volume with lower body mass index is associated with shorter survival in patients with amyotrophic lateral sclerosisJeryn Chang, Thomas B Shaw, Cory J Holdom, et al.
Journal of Neurology|February 5, 2023
Use of hip- versus wrist-based actigraphy for assessing functional decline and disease progression in patients with motor neuron diseaseCory J Holdom, Jordi W J van Unnik, Ruben P A van Eijk, et al.
European Journal of Neurology|July 3, 2021
Venous creatinine as a biomarker for loss of fat-free mass and disease progression in patients with amyotrophic lateral sclerosisCory J Holdom, Mark R Janse van Mantgem, Ruben P A van Eijk, et al.
Pageof 2